Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Di Rocco

Showing results (51-60 of 106) with videos related to

Pageof 11
Sort By:
Blood|May 4, 2018
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphomaLuca Ceriani, Lisa Milan, Maurizio Martelli, et al.
British Journal of Haematology|April 25, 2022
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamicsEleonora Calabretta, Anna Guidetti, Francesca Ricci, et al.
British Journal of Haematology|September 10, 2023
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomasAnna Dodero, Stefania Bramanti, Martina Di Trani, et al.
Hematological Oncology|May 25, 2022
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study)Luigi Rigacci, Roberta Battistini, Sofia Kovalchuk, et al.
In Vivo (Athens, Greece)|May 2, 2020
Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective StudyVitaliana DE Sanctis, Alice DI Rocco, Maria Christina Cox, et al.
British Journal of Haematology|December 14, 2011
Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genesIlaria Del Giudice, Monica Messina, Sabina Chiaretti, et al.
Leukemia & Lymphoma|June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective studyAngelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
British Journal of Haematology|December 24, 2021
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trialAnnalisa Chiappella, Fary Diop, Claudio Agostinelli, et al.
Leukemia & Lymphoma|September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano LinfomiFrancesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
British Journal of Haematology|June 15, 2024
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE studyAngelica Barone, Annalisa Chiappella, Beatrice Casadei, et al.
Pageof 11

Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
Blood|May 4, 2018
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphomaLuca Ceriani, Lisa Milan, Maurizio Martelli, et al.
British Journal of Haematology|April 25, 2022
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamicsEleonora Calabretta, Anna Guidetti, Francesca Ricci, et al.
British Journal of Haematology|September 10, 2023
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomasAnna Dodero, Stefania Bramanti, Martina Di Trani, et al.
Hematological Oncology|May 25, 2022
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study)Luigi Rigacci, Roberta Battistini, Sofia Kovalchuk, et al.
In Vivo (Athens, Greece)|May 2, 2020
Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective StudyVitaliana DE Sanctis, Alice DI Rocco, Maria Christina Cox, et al.
British Journal of Haematology|December 14, 2011
Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genesIlaria Del Giudice, Monica Messina, Sabina Chiaretti, et al.
Leukemia & Lymphoma|June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective studyAngelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
British Journal of Haematology|December 24, 2021
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trialAnnalisa Chiappella, Fary Diop, Claudio Agostinelli, et al.
Leukemia & Lymphoma|September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano LinfomiFrancesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
British Journal of Haematology|June 15, 2024
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE studyAngelica Barone, Annalisa Chiappella, Beatrice Casadei, et al.
Pageof 11